Form 8-K - Current report:
SEC Accession No. 0001213900-24-096007
Filing Date
2024-11-08
Accepted
2024-11-08 17:30:35
Documents
16
Period of Report
2024-11-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220438-8k_hoth.htm   iXBRL 8-K 29466
2 AT THE MARKET OFFERING AGREEMENT BY AND BETWEEN THE COMPANY AND H.C. WAINWRIGHT ea022043801ex1-1_hoth.htm EX-1.1 213437
3 OPINION OF SHEPPARD MULLIN RICHTER & HAMPTON, LLP ea022043801ex5-1_hoth.htm EX-5.1 13710
4 GRAPHIC ex5-1_001.jpg GRAPHIC 2825
  Complete submission text file 0001213900-24-096007.txt   497185

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE hoth-20241108.xsd EX-101.SCH 3039
6 XBRL LABEL FILE hoth-20241108_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE hoth-20241108_pre.xml EX-101.PRE 22375
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0220438-8k_hoth_htm.xml XML 3789
Mailing Address 590 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022
Business Address 590 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 241441996
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)